2022; Zhan et al. 2018). We have demonstrated that EA has therapeutic benefits in the animal models of stroke (Wang, Chen, et al. 2023; Fu et al. 2023), and recent findings suggest that EA can open the BBB without causing adverse effects (Zhang et al. 2018; Zhang, Gong, et al. 2020). The mechanism involved may be by activating the p65‐VEGFA‐TJs pathway and inhibiting the Shh‐Gli1 signaling pathway (Lin et al. 2023; Dai et al. 2025). The gene discussed is GLI1; the disease is stroke disorder.